Sat Sep 28 23:04:49 UTC 2024: ## Centene Stock Sees Mixed Signals: Susquehanna Sells, Others Buy

**New York, NY** – Centene Corporation (CNC), a major healthcare provider, saw a mixed bag of activity from institutional investors in the second quarter, according to filings with the Securities and Exchange Commission. Susquehanna Portfolio Strategies LLC reduced its stake in the company by 32%, while other firms like WR Wealth Planners LLC and Riverview Trust Co increased their holdings.

**Analyst Opinions Vary**

Analysts remain divided on Centene’s future prospects. Wells Fargo and Barclays both lowered their price targets, while TD Cowen and StockNews.com issued bullish ratings. Overall, the stock has a “Moderate Buy” rating with an average price target of $85.58, according to MarketBeat data.

**Earnings Miss Expectations**

Centene reported earnings per share of $2.42 for the second quarter, missing analyst estimates of $2.44. Revenue, however, exceeded expectations at $39.84 billion. Despite the earnings miss, analysts anticipate Centene will post $6.8 earnings per share for the current year.

**Stock Performance**

Centene’s stock opened at $74.57 on Friday, with a 50-day moving average of $75.06 and a 200-day moving average of $73.41. The company’s market capitalization is $39.79 billion.

**Investor Sentiment**

Institutional investors own 93.63% of Centene’s stock, suggesting strong institutional confidence. While Susquehanna’s sale may reflect a short-term outlook, other investors’ purchases indicate continued belief in the company’s long-term potential.

**Conclusion**

Centene’s stock faces mixed signals from institutional investors and analysts. While earnings missed expectations, the company continues to generate strong revenue. Investors will be watching closely to see how Centene navigates the evolving healthcare landscape and whether it can deliver on its growth potential.

Read More